Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Adicet Bio's ADI-001?
ADI-001 is a gene-modified cell therapy commercialized by Adicet Bio, with a leading Phase I program in B-Cell Non-Hodgkin Lymphoma....
ADI-001 by Adicet Bio for Marginal Zone B-cell Lymphoma: Likelihood of Approval
ADI-001 is under clinical development by Adicet Bio and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...
ADI-001 by Adicet Bio for Follicular Lymphoma: Likelihood of Approval
ADI-001 is under clinical development by Adicet Bio and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
ADI-001 by Adicet Bio for Mantle Cell Lymphoma: Likelihood of Approval
ADI-001 is under clinical development by Adicet Bio and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...